A5018602192- Respiratory and Cough-Related Research
- Pneumonia and Respiratory Infections
- Respiratory viral infections research
- Bone health and osteoporosis research
- Asthma and respiratory diseases
- Voice and Speech Disorders
- Pediatric health and respiratory diseases
- Bacterial Infections and Vaccines
- Pneumocystis jirovecii pneumonia detection and treatment
- Hip and Femur Fractures
- Immunodeficiency and Autoimmune Disorders
- Child and Adolescent Health
- Dysphagia Assessment and Management
- Vitamin D Research Studies
- Bone health and treatments
- Emergency and Acute Care Studies
- Tracheal and airway disorders
- Pelvic and Acetabular Injuries
- Pharmaceutical studies and practices
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Gastroesophageal reflux and treatments
- Ear Surgery and Otitis Media
- Endometriosis Research and Treatment
- Pregnancy-related medical research
- Medication Adherence and Compliance
Merck & Co., Inc., Rahway, NJ, USA (United States)
2015-2025
University of California, San Diego
2024
The prevalence and cost of subsequent fractures among patients with an incident fracture are not well defined.To assess the of, costs associated with, in year after fracture.This was a retrospective claims database analysis using data from Humana Medicare Advantage (Medicare group) Optum Insight Clinformatics Data Mart commercial (commercial group). Patients included study had claim for qualifying occurring between January 2008 December 2013 (index fracture), were continuously enrolled...
This study evaluated the clinical and economic impact of routine pediatric vaccination with 15-valent pneumococcal conjugate vaccine (PCV15, V114) compared 13-valent PCV (PCV13) from a societal perspective in United States (US). A Markov decision-analytic model was constructed to estimate outcomes for entire US population over 100-year time horizon. The estimated V114 versus PCV13 on disease (PD) incidence, post meningitis sequalae, deaths, taking herd immunity effects into account....
Abstract Background In France, effective pneumococcal conjugate vaccines (PCVs) and the high vaccine coverage rate (VCR) of 95% have led to a substantial decline in pediatric invasive disease (IPD) incidence. PCV13 is currently used 2+1 dosing regimen; PCV15 PCV20 are expected be introduced soon. Breakthrough IPD (bIPD), defined as fully vaccinated individuals who develop type IPD, persists for some serotypes (STs). As ST-specific immune responses decrease with increased PCV valency,...
Abstract Background Despite the success of pediatric pneumococcal conjugate vaccine (PCV) programs in US, acute respiratory illness, including otitis media (AOM) due to Streptococcus pneumoniae (SPN) persists. PCV13 has been recommended for routine use since 2010. With recent adoption higher-valency PCVs, there is a continued need survey pathogens causing AOM children.Table 1:Bacterial Results Nasal Specimens Children 6-35 Months Diagnosed with Acute Otitis Media (Cohorts 1&2) or Upper...
Objectives: Invasive pneumococcal disease incidence in children has decreased substantially since the introduction of conjugate vaccines (PCVs) against 7 (PCV7) and, later, 6 more (PCV13) serotypes (STs) clinically relevant US. In absence placebo-controlled vaccine efficacy trials, new PCVs are evaluated based on vaccine-induced, serotype-specific (SS) immune response levels (immunoglobulin G titers, IgGs), as they have been demonstrated to predict efficacy. New approved if induced SS IgGs...
Pneumococcal conjugate vaccines (PCVs) have been increasing in valency to protect against a larger number of serotypes; however, the addition serotypes has come at cost reduced immunogenicity, which may lead breakthrough disease. This study used mathematical model evaluate impact introducing routine vaccination with either PCV15 or PCV20 on invasive pneumococcal disease (bIPD) incidence associated PCV13 infants aged 0–12 months France. The incorporated historical PCV introductions and...
Introduction: In 2020 the UK National Immunization Programme reduced pediatric dosing schedule for pneumococcal vaccination with PCV13 from 2 doses in infancy followed by a toddler dose (2+1 schedule) to 1 (1+1 schedule). Real world data on vaccine effectiveness (VE) against invasive disease (IPD) under is not available, nor VE associated higher valency vaccines, including PCV15. This analysis investigates changes projected outcomes potential reductions IPD and PCV15 1+1 schedule. Methods: A...
International Classification of Diseases-9/10 codes for chronic cough (CC) do not exist, limiting investigation.
Abstract Background Acute otitis media (AOM) remains a common infection in children despite the introduction of pneumococcal conjugate vaccines. This study estimated AOM incidence rates (IRs) over time < 16 years old Germany following PCV13 introduction. Methods episodes were identified InGef healthcare claims database from 2014–2019 aged years. Each episode was classified as either simple or recurrent. Recurrent defined 3 more within 6-month period; 4 12-month period with at least one...
Background: Chronic cough (CC) affects about 10% of adults, but opioid use in CC is not well understood. Objectives: To determine the opioid-containing suppressant (OCCS) prescriptions patients with using electronic health records. Design: Retrospective cohort study. Methods: Through retrospective analysis Midwestern U.S. records, diagnoses, prescriptions, and natural language processing identified – at least three medical encounters cough, 56–120 days between first last encounter a...
Background Next-generation, higher-valency pneumococcal conjugate vaccines (PCVs), 15-valent PCV V114 and 20-valent (PCV20), have been assessed by comparing their immune responses across serotypes shared with the 13-valent (PCV13). Without efficacy or real-world vaccine effectiveness (VE) it becomes important to relate IgG titers VE aid in interpretation of response elicited PCV20.
Background Next generation, higher valency pneumococcal conjugate vaccines (PCVs) are assessed and licensed by comparing the immune response across serotypes shared with PCVs that standard of care for prevention disease.
As higher-valent pneumococcal conjugate vaccines (PCVs) become available for pediatric populations in the US, it is important to understand healthcare provider (HCP) preferences and acceptability of PCVs. US HCPs (pediatricians, family medicine physicians advanced practitioners) completed an online, cross-sectional survey between March April 2023. were eligible if they recommended or prescribed children age <24 months, spent ≥25% their time direct patient care, had ≥2 y experience...
Objective: To investigate patterns of presentation cough in primary care and develop an algorithm to identify probable possible chronic (CC).Methods: This retrospective observational study used routine English data linked hospital data. Patients with ≥1 event the period (March 2014–February 2015) were selected. Index date was that earliest this period. Adults (aged ≥18 years) classified as having CC if they had explicit diagnosis; ≥3 events recorded over 8–26 weeks; or, otherwise, acute...
Abstract Background Chronic cough (CC) is difficult to identify in electronic health records (EHRs) due the lack of specific diagnostic codes. We developed a natural language processing (NLP) model free-text provider notes EHRs from multiple care providers with objective using rules-based CC algorithm individuals and describe demographic clinical characteristics CC. Methods This was retrospective observational study enrollees Optum’s Integrated Clinical + Claims Database. Participants were...
Pneumococcal disease (PD) is a major cause of morbidity and mortality among children, particularly in the youngest age groups. This study aimed to assess incidence PD over time by group young children with commercial or Medicaid coverage US. Episodes invasive pneumococcal (IPD), all-cause pneumonia (ACP), acute otitis media (AOM) were identified MarketScan® Commercial claims databases using diagnosis codes aged ≤ 48 months confirmed date birth (DoB), at any during period (1998–2019). DoB was...
Although treatment for osteoporosis is recommended by U.S. clinical guidelines, a lack of diagnosis and common among patients with osteoporotic fractures.To determine the rates before after various types fractures.This was retrospective claims analysis using data from Humana Medicare Advantage (Medicare group) Optum Insight Clinformatics Data Mart commercial (Commercial group). Patients included in study had claim qualifying fracture occurring between January 2008 December 2013 (the index...
The potential impact of new pneumococcal conjugate vaccines (PCVs) is assessed by using immune responses to predict their effectiveness against invasive disease (IPD). This analysis predicted the serotype-specific IPD a 15-valent PCV (V114) for serotypes shared with 13-valent (PCV13), in US pediatric population given 3 + 1 dosing regimen.Beginning known antibody concentrations after vaccination placebo, 7-valent (PCV7) and PCV13, reverse cumulative distribution curves were used, along...
The Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC-OS) is a prospective, observational study women with osteoporosis in Europe Canada. At baseline, patients gastrointestinal symptoms reported lower adherence to treatment, treatment satisfaction, health-related quality life, than those without symptoms. aim the was examine (GI) association between GI adherence, life (HRQoL) among osteoporotic Baseline results are here for prospective which...